Novavax, Fujifilm begin large-scale manufacturing of COVID-19 vaccine

By The Science Advisory Board staff writers

July 24, 2020 -- Novavax and Fujifilm Diosynth have signed an agreement covering the bulk manufacture of Novavax's COVID-19 vaccine candidate, NVX-CoV2373, at Fujifilm's Morrisville, NC, facility.

The large-scale manufacture of the vaccine candidate is part of the $1.6 billion award from the U.S. government's Operation Warp Speed. The award covers late-stage clinical development, including a phase III clinical trial and funds to establish large-scale manufacturing to enable the delivery of 100 million doses of the vaccine as early as late 2020.

Manufactured doses from the Fujifilm North Carolina site will be utilized in the phase III clinical trial of up to 30,000 subjects, which is expected to begin in the fall of 2020.

NVX-CoV2373 is a stable prefusion protein using Novavax's proprietary nanoparticle technology and adjuvant. Fujifilm will provide manufacturing capabilities and baculovirus expression system expertise to help deliver the 100 million doses.

Copyright © 2020
To access all The ScienceBoard content create a free account now:

Email Address:  

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

Letter from the Editor Please send me twice-weekly roundups of all the latest life research and industry news.
SAB Announcements Please send me the latest announcements from The Science Advisory Board and their partners.
Spotlight Receive notifications about new content, services, or educational resources designed to help you sharpen your skills and grow professionally.
I have read and agree to the privacy policy and terms of service and wish to opt-in for

Already have an account? Sign in here